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Previous research evaluating the use of adjuvant endocrine therapy among postmenopausal breast cancer patients showed with
15–50% wide ranges of non-adherence rates. We evaluated this issue by analysing an unselected study group comprising of 325
postmenopausal women, diagnosed from 1997 to 2003 with hormonal receptor-positive invasive breast cancer. The different clinical
situations that led to the discontinuation of adjuvant endocrine therapy were clearly defined and differentiated: non-adherence was
not simply the act of stopping medication, but rather the manifestation of an intentional behaviour of the patient. Of the 287 patients
who initiated endocrine therapy, 191 (66.6%) fully completed this treatment. Thirty-one patients (10.8%) showed non-adherence to
therapy. Patients who had follow-up with a general practitioner, rather than in an oncologic unit, were more likely to be non-adherent
(P¼0.0088). Of 25 patients who changed medication due to therapy-related adverse effects, 20 (80%) patients fully completed the
therapy after drug change. In adjuvant endocrine therapy, a lowering of the non-adherence rate to 10.8%, the lowest reported in the
literature, is realistic when patients are cared for by a specialised oncologic unit focusing on the individual needs of the patients.
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Since the late 1990s, adjuvant systemic endocrine therapy was
recommended for the vast majority of postmenopausal patients
with hormonal receptor (HR)-positive breast carcinomas. The
sixth St Gallen International Consensus Panel on the Treatment
of Primary Breast Cancer refined these guidelines in 1998: with
the exception of low-risk, node-negative patients, the panel
recommended a full 5 years of tamoxifen therapy for all elderly
women with HR-positive breast cancer (Goldhirsch et al, 1998).
More recently, clinical studies demonstrated additional benefit
with aromatase inhibitors in postmenopausal women, either as
initial management or following a period of tamoxifen use
(Coombes et al, 2004; Coates et al, 2007; Forbes et al, 2008).
In long-term therapy, however, there are a multitude of factors
and clinical situations that prevent and threaten the completion of
the targeted 5-year treatment. Patient refusal to initiate the
recommended antihormonal medication and non-adherence to
therapy (defined as a composite of compliance and persistence: the
patient started therapy, but discontinued the planned treatment)
are important, but are not the only contributors. Both factors were
evaluated in several studies, in clinical trials (Fisher et al, 1989;
Coombes et al, 2004; Coates et al, 2007; Forbes et al, 2008) and
in clinical practise settings (Waterhouse et al, 1993; Demissie et al,
2001; Silliman et al, 2002; Partridge et al, 2003, 2008; Fink et al,
2004; Grunfeld et al, 2005; Atkins and Fallowfield, 2006; Lash
et al, 2006; Barron et al, 2007; Owusu et al, 2008). These studies,
however, evaluated only selected populations and failed to describe
all the possible situations that determine compliance and
adherence to therapy in everyday clinical settings.
Our study depicts the entire picture of the adjuvant treatment
setting in postmenopausal women. This approach was made
possible by considering the entire group of all postmenopausal
patients with non-metastatic breast cancer (diagnosed and
surgically treated in a 7-year period from 1997 to 2003), whose
carcinomas were HR–positive, and therefore were candidates for
adjuvant endocrine therapy. We define and evaluate the diverse
clinical situations that hinder the realisation of the target of a
complete 5-year therapy.
PATIENTS AND METHODS
Data regarding all postmenopausal non-metastatic breast cancer
patients, who received surgical therapy between 1997 and 2003 at
the Department of Gynaecology and Obstetrics of the University
Hospital Basel (Basel, Switzerland), form the basis of the current
analysis. Of these 393 patients, 325 had HR-positive carcinomas
(82.7%) and 68 had HR-negative tumours (17.3%). The 325
patients with HR-positive carcinomas were evaluated in this study.
We had complete follow-up in 323 of these patients, whereas two
patients were lost to follow-up, one after 3 months and the other
after 12 months.
The following data were collected from the medical records
and were available for all patients: age at initial diagnosis, tumour
stage according to the American Joint Committee on Cancer
(AJCC)/International Union Against Cancer (UICC) TNM Classi-
fication, histologic subtype, grading, oestrogen receptor (ER) and
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sprogesterone receptor (PR) status, surgery type, and receipt of
adjuvant chemotherapy and/or radiation. HER-2/neu status was
available for 273 patients (84.0%).
The treatment recommendations for all patients were based
on the decision of the interdisciplinary tumour board of the
University Hospital Basel. Since 1997, all HR-positive patients,
with few exceptions, were recommended to have adjuvant
endocrine therapy. All patients received a comprehensive
consultation at the departmental oncology unit during which the
treatment indication and duration, as well as the potential adverse
effects, were extensively discussed.
The prescribed antihormonal agent given was recorded. To
systematically evaluate the different clinical situations during the
course of adjuvant endocrine therapy, we created the following
subdivisions:
(A) Patients who did not initiate therapy
This subgroup includes the patients to whom endocrine therapy
was not recommended, and the patients who refused the
recommended therapy and never began treatment.
(B) Patients who initiated therapy
This subgroup includes the patients who completed the therapy
after a 5-year course (for the patients diagnosed in 2003, we had
a follow-up for at least 4 years). Patients with extended
therapy 45 years were also considered as having fully completed
therapy. Further subgroups must also be considered as having
completed therapy, although treatment was not administered
during the targeted 5 years: discontinuation due to death, as
well as discontinuation due to breast cancer recurrence (local
and/or distant metastases) and serious medical reasons inde-
pendent from breast cancer disease and therapy-related
adverse effects. We distinguished the above-mentioned subgroups
from non-adherent patients who discontinued the planned
mode of treatment and refused to continue further endocrine
therapy.
Furthermore, we recorded any change of endocrine agents and
the indication for the change: sequential therapy (switching after
2–3 years of adjuvant tamoxifen therapy to an aromatase
inhibitor), extended therapy beyond 5 years of adjuvant therapy
or change due to adverse effects. Lastly, we recorded the location
of treatment and follow-up of the patients (our own oncology unit,
external oncology unit or general practitioner).
Information concerning type and length of the medication, as
well as the reasons for discontinuation, was retrospectively
obtained from the medical record. Patients who had no follow-
up at our institution were contacted via telephone. Afterwards,
contact was made with the treating physician to confirm the
patients’ statements.
The study design and data collection methods were approved by
the Institutional Review Board.
Statistical analysis
To identify factors associated with treatment refusal and non-
adherence, we created two univariate logistic regression models.
Each model included the independent variables: year of the initial
diagnosis, patient’s age, primary surgical therapy, tumour stage,
receipt of previous chemotherapy and/or postoperative radiation,
and location of follow-up (the latter only in the non-adherence
model). Odds ratios (ORs) with corresponding 95% confidence
intervals (CIs) were reported; a P-value less than 0.05 was
considered significant. Statistical analyses were performed with R
Development Core Team Software (version 2.5.0, Vienna, Austria).
RESULTS
The clinicopathologic, treatment and follow-up characteristics of
the 325 patients in the study are summarised in Tables 1–3.
(A) Patients who did not initiate endocrine therapy (n¼38)
In 10 cases, despite HR-positive carcinoma, a recommendation
for endocrine therapy was not made. The reasons for this
included a low-risk constellation (pT1a/b N0, favourable grading)
and/or advanced age with considerable comorbidity. Twenty-eight
patients (8.9%) refused the recommended endocrine therapy
after extensive counselling and never began this treatment.
Univariate analysis revealed that older patients, those who were
initially diagnosed at the beginning of the study period
and those who did not receive adjuvant chemotherapy were
more likely to refuse therapy (advanced age: P¼0.019; study
period: 1997–2000 vs 2001–2003: P¼0.0070; no chemotherapy:
Po0.0001;Table 4). Additionally, patients who had a favourable
disease stage (stage I) tended to refuse the recommended therapy
(P¼0.0546).
Table 1 Clinicopathologic and treatment characteristics of 325 post-
menopausal women with hormonal receptor-positive breast cancer
Variable Number (%)
Age (years)
Mean 67.3
Range 47–95
p60 years 100 (30.8)
61–75 years 152 (46.8)
475 years 73 (22.4)
Hormonal receptor status
ER+ PR+ 231 (71.1)
ER+ PR  89 (27.4)
ER  PR+ 5 (1.5)
Grading
G1 74 (22.8)
G2 166 (51.1)
G3 85 (26.1)
HER-2 neu status
Known 273 (84.0)
Positive 42 (15.4)
Histologic subtype
Ductal invasive 233 (71.7)
Lobular invasive 62 (19.1)
Rare types 30 (9.2)
AJCC/UICC stage
a
I 144 (44.3)
IIA 134 (41.2)
III 47 (14.5)
Type of surgery
Mastectomy+ALND 101 (31.1)
Mastectomy+SLND 4 (1.2)
BCT+ALND 143 (44.0)
BCT+SLND 39 (12.0)
Mastectomy only 23 (7.1)
Tumorectomy only 15 (4.6)
Systemic treatment, others than adjuvant endocrine therapy
Previous adjuvant chemotherapy 49 (15.1)
Neoadjuvant chemotherapy 4 (1.2)
Neoadjuvant endocrine therapy 2 (0.6)
Adjuvant treatment with trastuzumab 2 (0.6)
Adjuvant radiotherapy 196 (60.3)
AJCC¼American Joint Committee on Cancer; ALND¼auxiliary lymph node
dissection; BCT¼breast conserving therapy; ER¼estrogen receptor; PR¼proges-
terone receptor; SLND¼sentinel lymph node dissection; UICC¼International
Union Against Cancer.
aIn six patients, where neoadjuvant therapy was performed,
the ypT and ypN status were used for stage grouping.
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s(B) Patients who initiated endocrine therapy (n¼287)
The initial endocrine agents prescribed are listed in Table 2.
Forty-five patients were treated within the randomised, phase III,
double-blind Breast International Group (BIG) 1-98 four-arm
study (letrozole or tamoxifen as monotherapy or sequential
therapy) (Coates et al, 2007). The medication was unblinded
in 25 of these patients. Even when the study drug had been
unblinded, these cases were listed under the category ‘study
medication (BIG 1-98)’. Of the 45 BIG 1-98 study patients,
30 (66.7%) had completed 5 years of treatment according to the
study guidelines. Of the 14 patients who prematurely discontinued
their randomly assigned trial medication for reasons other than
disease recurrence, 8 women fully completed the endocrine
therapy over a 5-year course outside of the trial (57.3%).
In 50 patients, there was a change of the antihormonal agent
prescribed within the planned 5-year period. Of these, four
patients changed their medication twice and one patient three
times. Twenty-five of the 50 patients changed their medication
due to adverse effects of the endocrine therapy (three changed the
Table 2 Endocrine therapy regimen
Number
(%)
Initial agent prescribed
Tamoxifen 206 (63.4)
Anastrozol 18 (5.5)
Letrozole 18 (5.5)
Study medication (BIG 1-98 trial) 45 (13.8)
Change of the agent prescribed
Owing to adverse effects 30
Sequential therapy (switching after 2–3 years of adjuvant
tamoxifen therapy
a
26
Extended therapy beyond 5 years of adjuvant tamoxifen therapy 23
Change of the agent prescribed within the 5-year period of treatment
(excluding patients with change of the regimen due to extended therapy)
Study medication (BIG 1-98)-tamoxifen 4 (7.1)
Study medication (BIG 1-98)-aromatase inhibitor 6 (10.7)
Tamoxifen-aromatase inhibitor 37 (66.1)
Aromatase inhibitor-tamoxifen 3 (5.4)
Aromatase inhibitor-aromatase inhibitor 6 (10.7)
Change of the agent prescribed within the 5-year period of treatment
due to adverse effects
Study medication (BIG 1-98)-tamoxifen 4 (13.3)
Study medication (BIG 1-98)-aromatase inhibitor 4 (13.3)
Tamoxifen-aromatase inhibitor 14 (46.7)
Aromatase inhibitor-tamoxifen 4 (13.3)
Aromatase inhibitor-aromatase inhibitor 4 (13.3)
BIG¼Breast International Group.
aOwing to medication blinding, switching
endocrine therapy within the BIG 1-98 trial was not considered.
Table 3 Course of endocrine therapy
Number (%)
Mean age
(range)
Median duration of
therapy (months)
Entire study group 325
No endocrine therapy recommended 10 (3.1) 76.8 (51–95)
Patients where endocrine therapy was recommended 315 (100)
Patients refused to initiate therapy 28 (8.9) 70.4 (51–89)
Patients who initiated endocrine therapy 287 (100)
Therapy fully completed 191 (66.6) 65.0 (47–85)
Therapy discontinued due to death (i.e., completed) 11 (3.8) 81.4 (69–88) 12 (4–48)
Therapy discontinued due to breast cancer recurrence (i.e., completed) 43 (15.0) 67.1 (48–86) 28 (4–58)
Therapy stopped due to medical reasons independent from breast
cancer and adverse effects from the endocrine therapy
9 (3.1) 76.0 (52–91) 28 (5–52)
Non-adherence 31 (10.8) 67.3 (51–85) 19 (1–50)
Lost to follow-up 2 (0.7)
Table 4 Univariate relationships between potential predictors and
refusal of recommended endocrine therapy (A) and non-adherence to
therapy (B)
Variable Odds ratio 95% CI P-value
(A) Refusal of recommended therapy (n¼28)
Year of the initial diagnosis
2001–2003 Reference
1997–2000 3.07 1.36–6.94 0.0070
Advanced age 1.54
a 1.07–2.21 0.0190
TNM disease stage
b
Stage II/III Reference
Stage I 2.12 0.99–4.57 0.0546
Primary surgical therapy
BCT Reference
Mastectomy 1.31 0.59–2.91 0.5010
No previous chemotherapy 38.83 11.32–133.16 o0.0001
Postoperative radiation 1.82 0.85–3.87 0.1211
(B) Non-adherence (n¼31)
Year of the initial diagnosis
2001–2003 Reference
1997–2000 1.10 0.52–2.32 0.8115
Advanced age 1.09
a 0.75–1.60 0.6501
TNM disease stage1
Stage II/III Reference
Stage I 1.37 0.65–2.90 0.4044
Primary surgical therapy
BCT Reference
Mastectomy 1.43 0.65–3.17 0.3748
No previous chemotherapy 2.23 0.65–7.64 0.2013
Postoperative radiation 1.82 0.86–3.84 0.1186
Location of follow up
Oncologic unit Reference
General practitioner 2.78 1.29–5.98 0.0088
BCT¼breast conserving therapy.
aOdds ratio is expressed as the ratio of an increase
within 10 years.
bAJCC (American Joint Committee on Cancer)/UICC (International
Union Against Cancer) TNM Classification.
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smedication twice and one three times). Of these, 20 patients (80%)
fully completed the therapy after drug change.
The therapy course, reported in Tables 3 and 5, was as follows:
Of the 287 patients who initiated endocrine therapy, 191 (66.6%)
fully completed the targeted therapy (four patients interrupted
therapy for up to 3 months, another for 5 months). Eleven patients
(3.8%) discontinued the therapy due to death, whereas 43 patients
(15.0%) ceased therapy due to breast cancer recurrence. In nine
cases (3.1%), the therapy was discontinued by the physician due to
serious medical reasons independent from breast cancer disease
and therapy-related adverse effects (advanced age/dementia/need
for nursing home care, n¼5; incurable malignancy other than
breast cancer, n¼3; irreversible coma following severe head
trauma, n¼1).
Non-adherence: Thirty-one patients (10.8%) chose indepen-
dently to end the therapy. The main reasons for this given by the
patients are listed in Table 5. In the seven variables used in our
univariate analyses, location of follow-up was the only significant
predictor, showing that patients who did not have follow-up in an
oncologic unit, but rather with a general practitioner, were more
likely to be non-adherent to therapy (P¼0.0088; Table 4).
Location of follow-up: Of the 289 patients who received adjuvant
endocrine therapy, 215 (74.4%) were treated in an oncology unit;
of these, 194 patients in the internal oncology unit (67.1%) and 21
(7.3%) in an external oncologic unit. Seventy-two patients (24.9)
had further follow-up and treatment through a general practi-
tioner. Two patients (0.7%) were lost to follow-up, and the location
of the oncologic care was unknown.
DISCUSSION
Although several studies performed in clinical practise settings
(Waterhouse et al, 1993; Demissie et al, 2001; Silliman et al, 2002;
Partridge et al, 2003, 2008; Fink et al, 2004; Grunfeld et al, 2005;
Atkins and Fallowfield, 2006; Lash et al, 2006; Barron et al, 2007;
Owusu et al, 2008) and clinical trials (Fisher et al, 1989; Coombes
et al, 2004; Coates et al, 2007; Forbes et al, 2008) have addressed
non-adherence to endocrine therapy for breast cancer, the
conclusions that can be drawn from the currently available
evidence are significantly limited. The reported rates of non-
adherent patients in adjuvant endocrine therapy of breast cancer
range considerably from 15 to 50%. The great variability of the
data can only be adequately interpreted when the basic methods of
each study are closely analysed. Within the current literature, there
exist major non-uniformities and shortcomings, which make
useful insights for a current general population difficult. Some of
the critical points include
  All studies exclusively analysed selected study cohorts.
  Some studies used insurance claims and public health data
(Partridge et al, 2003, 2008; Barron et al, 2007). However,
analyses of public databases, which record patient data only to
the extent that was necessary for administrative statistical
purposes, are not always able to provide information concern-
ing the often very individual clinical situations and reasons that
lead to the cessation of medication.
  In some studies, it must be assumed that also patients who
never took the medication, that is patients who received the
prescription but refused therapy from beginning, were also
considered (Partridge et al, 2003, 2008; Barron et al, 2007).
  Most clinical practise studies only analysed a predominantly
geriatric study group (Silliman et al, 2002; Partridge et al, 2003;
Fink et al, 2004; Lash et al, 2006; Barron et al, 2007; Owusu et al,
2008).
  The data are difficult to compare due to variable observation
periods, which included 17 months (Silliman et al, 2002), over
3 (Demissie et al, 2001; Barron et al, 2007; Partridge et al, 2008),
4 (Partridge et al, 2003), and up to 5 (Fink et al, 2004; Lash et al,
2006; Owusu et al, 2008) years.
  Large part of the published studies are not applicable today,
since initial diagnosis and the start of adjuvant treatment took
place in the 1990s when the indication for therapy was usually
limited to patients with stage II/III disease (Demissie et al, 2001;
Silliman et al, 2002; Partridge et al, 2003; Fink et al, 2004; Lash
et al, 2006; Owusu et al, 2008). In contrast, endocrine therapy is
recommended for nearly all HR-positive breast cancer patients
according to the most current guidelines (Goldhirsch et al,
2007). Only two studies have reported results from data
obtained in a contemporary study period after 2001 (Barron
et al, 2007; Partridge et al, 2008).
It should be the goal of studies concerning the use of endocrine
therapy to identify the rate of patient non-compliance and non-
adherence and to evaluate the characteristics of these patients. A
certain proportion of these patients may be potentially motivated
to initiate and to maintain therapy by more intensive care and
improved counselling. In our view, non-adherence is not simply
the act of stopping medication, but rather the manifestation of an
intentional behaviour. The reasons for non-adherence, such as
distressing adverse effects, inadequate clarification of the benefits
of therapy, and fear and mistrust of the agent prescribed, can be
elucidated in most cases. An important aspect of non-adherence to
treatment is the ability of physician to intervene and change the
attitude that led to the discontinuation. To separately analyse the
subgroup of non-adherent patients, the clinical situations that
result in a discontinuation of medication must be clearly defined.
Particularly, patients who refused the recommended therapy
or were non-adherent (whose attitude and behaviour may be
potentially influenced) and those whose therapy had to be stopped
due to breast cancer recurrence or other serious medical reasons
(that is, discontinuation of the therapy was unavoidable) must not
be analysed in one collective study group.
A realisation of this goal requires a careful and detailed clinical
follow-up of the study group and a clear discrimination between the
terms and reasons behind ‘discontinuation’ and ‘non-adherence’.
The currently available studies from clinical practise settings have
not been able to accomplish this. In most of these studies, patients
who discontinued therapy, regardless of the reason for cessation,
were categorised in a single group, and the terms ‘discontinuation’
and ‘non-adherence’ were used synonymously (Waterhouse
et al, 1993; Silliman et al, 2002; Partridge et al, 2003, 2008;
Fink et al, 2004; Grunfeld et al, 2005; Atkins and Fallowfield, 2006;
Lash et al,2 0 0 6 ;B a r r o net al, 2007; Owusu et al, 2008).
Large clinical trials, with their extensive case documentation
requirements, also cannot provide exact information regarding
adherence to endocrine therapy in the general setting, as the
Table 5 Non-adherence to endocrine therapy: main reasons for and
period of discontinuation in 31 non-adherent patients
Number (%)
Main reasons for discontinuation
Without reporting complaints 11 (35.5)
Intolerance, general discomfort and malaise 9 (29.0)
Hot flushes 4 (12.9)
Dermatologic symptoms/hair loss 3 (9.7)
Visual disturbances 1 (3.2)
Alcohol dependency or psychiatric disease 3 (9.7)
Period of discontinuation (year of therapy)
First year 12 (38.7)
Second year 6 (19.4)
Third year 9 (29.0)
Fourth year 3 (9.7)
Fifth year 1 (3.2)
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sreadiness to participate in a trial already creates a certain selection
bias. In trials that compared tamoxifen with an aromatase
inhibitor, the rates of non-adherence are clearly lower than those
reported in clinical practise studies, and within those trials, the
variabilities in rates were minor (tamoxifen: 11–13%, aromatase
inhibitors: B12%) (Coombes et al, 2004; Coates et al, 2007;
Forbes et al, 2008). The NSABP B-14 trial, conducted in the
1980s, revealed a non-adherence rate with tamoxifen of 16.8%;
remarkably, non-adherence to placebo was also comparatively
high (14.9%) (Fisher et al, 1989). Non-adherence data from clinical
trials may not necessarily be transferable to general practise, as
the withdrawal of study medication does not imply the stop of
endocrine therapy. In our analysis, 8 out of 14 patients who
stopped the study medication in the BIG 1-98 trial due to other
reasons than breast cancer recurrence continued and completed
endocrine therapy outside of the trial.
The conclusions of all currently available studies can only give
more or less reliable information regarding the use of endocrine
therapy for postmenopausal breast cancer in clinical practise
today. In our study, we avoided many of the above-mentioned
methodological problems:
  We formulated our study group following current guidelines,
which indicate endocrine therapy based on menopausal status,
and not on a defined age.
  We utilised a more population-based approach by analysing and
following all surgically treated postmenopausal patients in a
7-year period; through this, we were able to minimise selection
bias.
  The data reflect the current situation, as a period was analysed
in which the currently valid guidelines of treatment recommen-
dations (Goldhirsch et al, 2007) were active.
  We provided careful and detailed clinical follow-up with clear
differentiation of the situations that led to discontinuation of
therapy.
  We used a clear definition of the term ‘non-adherence’.
We did not differentiate between antihormonal agents
prescribed in our study based on the finding from clinical trials
that adherence to aromatase inhibitors and tamoxifen did not
differ significantly (Chlebowski and Geller, 2006).
The rate of non-adherence to adjuvant endocrine therapy in
our study was with 10.8% considerably lower than that reported in
most other clinical practise settings (21–50%) (Partridge et al,
2003, 2008; Fink et al, 2004; Lash et al, 2006; Barron et al, 2007;
Owusu et al, 2008); these studies, however, were plagued by the
previously mentioned methodological weaknesses. With a non-
adherence rate of 15% after a 3-year observation period, Demissie
et al (2001) had findings most similar to ours. Not surprisingly,
they avoided the major methodical shortcoming of other studies,
in that they excluded patients who stopped therapy due to breast
cancer recurrence from the group of non-adherent patients. When
compared to the non-adherence rates reported in clinical trials
(approximately 12%; Coombes et al, 2004; Coates et al, 2007;
Forbes et al, 2008), our results appear realistic.
Several studies performed in a clinical practise setting demon-
strated that adherence to endocrine therapy was influenced by
certain factors such as age, adverse effects, patient beliefs about the
risks and benefits of tamoxifen use, history of medication and
good patient–doctor relationship (Chlebowski and Geller, 2006).
Some of these factors may be influenced by the type of care and
expertise of the responsible physician. Our study shows that care
in an oncologic unit is significantly associated with higher
adherence to therapy (non-adherence in the subgroup of patients
who had follow-up in an oncologic unit was even as low as 7.4%).
The finding that care in an oncologic unit is associated with higher
adherence may not necessarily be a reason for optimism. With
more and more numbers of cancer patients being treated with oral
agents and limitations on specialists’ time, a better strategy
might be to develop improved collaboration with primary care
physicians.
As most of the patients of our study were treated at the oncology
unit of our department, the favourable non-adherence rates are
probably associated with the fact that all practitioners received a
targeted education in the techniques of patient-centred communica-
tion through the departmental division of psychosomatic medicine.
These communication skills were applied in the follow-up of
oncologic patients, in particular regarding the dialogue concerning
possible therapy-related side effects and the importance of
compliance and adherence to therapy (Mallinger et al, 2005; Stewart
et al, 2007). Although endocrine therapy for postmenopausal breast
cancer is generally well tolerated and the majority of adverse effects
are mild to moderate, there are a certain number of patients who
experience these as distressing (above all, hot flushes, musculoske-
letal complaints/arthralgia and vaginal dryness). These effects should
be carefully evaluated and regarded seriously in the follow-up
appointments making the patients feel that their complaints are
taken earnestly. As stated by other authors, a change in therapy may
be an effective strategy to improve patient adherence (Hadji, 2008).
In our study, 80% of the patients who required a change of the
prescribed agent due to adverse effects could fully complete
endocrine therapy in the course of time.
The limitations of our retrospective study, however, must be
considered. First, our study relies on information obtained by
patients’ self-report of adherence. It is possible that in some cases,
the patients who reported continuing to take medication had
indeed stopped taking it and just gave a socially acceptable answer.
Furthermore, we defined non-adherence as an intentional beha-
viour. Atkins and Fallowfield (2006) demonstrated a high
percentage of 55% of non-adherent patients with the vast majority
of women reporting a non-intentional non-adherence, that is they
often just forgot to take their medication. On the other hand, we
think that it is unlikely that women would report that they had
stopped taking medication when in fact they had not. In this
context, the findings of Waterhouse et al (1993) must also be
considered; they examined the influence of methodology on the
categorisation of adherence to tamoxifen therapy and found that
self-reported adherence fairly consistently underestimates non-
adherence as determined by more objective measures, such as pill
count and microelectronic monitoring. A second caveat may be
that our study comes from a single region of a small country with a
high socioeconomic status. All inhabitants of Switzerland have
universal access to health care and free access to all prescribed and
approved drugs. These facts must be considered while interpreting
our relatively low non-adherence rate.
Our data show that, when compared with other studies, low
non-adherence rates can be realistically achieved. In the future,
multifactorial approaches should be further analysed and refined
with the goal of further improving compliance and adherence, and
by doing so, the outcome of breast cancer patients (Chlebowski
and Geller, 2006).
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